A meta-analysis of randomized trials for effects of periprocedural atorvastatin on contrast-induced nephropathy

International Journal of Cardiology

Volumn 153, Issue 3, 2011, Pages 323-325

  Takagi, Hisato ^a   Umemoto, Takuya ^a  

^a SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

Atorvastatin; Contrast induced nephropathy; Meta analysis; Randomized controlled trial

Indexed keywords

ATORVASTATIN; CREATININE; PLACEBO; SIMVASTATIN;

ANGIOGRAPHY; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG TARGETING; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; LETTER; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SHORT COURSE THERAPY; SYSTEMATIC REVIEW;

EID: 81855220843     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.08.047     Document Type: Article

References (23)

1. T. Zhang, L.H. Shen, L.H. Hu, and B. He Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis Am J Nephrol 33 2011 344 351
2. H. Ozhan, I. Erden, and S. Ordu Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography Angiology 61 2010 711 714
3. A. Toso, M. Maioli, and M. Leoncini Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease Am J Cardiol 105 2010 288 292
4. Z. Wang, H. Chen, Y. Pan, C. Gao, G. Dong, and S. Yang Effect of atorvastatin on renal function in patients given contrast medium after interventional procedures Med J Chin People's Armed Police Forces 20 2009 919 922
5. X. Zhou, Y.Z. Jin, Q. Wang, R. Min, and X.Y. Zhang Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography Zhonghua Xin Xue Guan Bing Za Zhi 37 2009 394 396
6. J.P. Higgins, J.J. Deeks, editors. Chapter 7: Selecting studies and collecting data. In: Higgins JP, Deeks JJ, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
7. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634 (Pubitemid 27387172)
8. S. Acikel, H. Muderrisoglu, and A. Yildirir Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography Blood Coagul Fibrinolysis 21 2010 750 757
9. G. Patti, E. Ricottini, and A. Nusca Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Contrast-Induced Nephropathy] Trial Am J Cardiol Apr. 27 2011 [Epub ahead of print]
10. G.L. Chen, and J.Z. Su Atorvastatin attenuated contrast induced renal function damage Zhonghua Xin Xue Guan Bing Za Zhi 37 2009 389 393
11. L. Zhang, L. Zhang, and Y. Lu Efficacy of statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis of randomised controlled trials Int J Clin Pract 65 2011 624 630
12. P.A. McCullough Contrast-induced acute kidney injury. J Am Coll Cardiol 2008;51:1419-28. Erratum in J Am Coll Cardiol 51 2008 2197
13. J. Tumlin, F. Stacul, and A. Adam Pathophysiology of contrast-induced nephropathy Am J Cardiol 98 2006 14K 20K
14. G.L. Bakris, N. Lass, A.O. Gaber, J.D. Jones, and J.C. Burnett Jr. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals Am J Physiol 258 1990 F115 F120
15. T. Ichiki, K. Takeda, and T. Tokunou Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells Arterioscler Thromb Vasc Biol 21 2001 1896 1901 (Pubitemid 34219738)
16. O. Hernández-Perera, D. Pérez-Sala, and J. Navarro-Antolín Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells J Clin Invest 101 1998 2711 2719 (Pubitemid 28294580)
17. P.O. Bonetti, L.O. Lerman, C. Napoli, and A. Lerman Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 24 2003 225 248 (Pubitemid 36207079)
18. G. Patti, M. Chello, and V. Pasceri Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy J Am Coll Cardiol 48 2006 1560 1566 (Pubitemid 44528186)
19. Y. Rikitake, S. Kawashima, and S. Takeshita Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits Atherosclerosis 154 2001 87 96 (Pubitemid 32008567)
20. J.C. Mason, Z. Ahmed, and R. Mankoff Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury Circ Res 91 2002 696 703 (Pubitemid 35204952)
21. D. Lecian, H. Demova, and A. Lodererova Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis Kidney Blood Press Res 29 2006 135 143 (Pubitemid 44597752)
22. J. Li, Y.M. Sun, L.F. Wang, Z.Q. Li, W. Pan, and H.Y. Cao Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease Clin Cardiol 33 2010 222 227
23. Y. Su, Y. Xu, and Y.M. Sun Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus J Cardiovasc Pharmacol 55 2010 21 25